Preventing low platelets from chemotherapy in breast cancer
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This trial tests whether a drug called hetrombopag can prevent dangerously low platelet counts (cells that help blood clot) in breast cancer patients receiving chemotherapy. It is for people who experienced very low platelets from a previous round of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with breast cancer
- You are receiving or will receive chemotherapy in cycles of at least 3 weeks
- Your platelet count dropped below 50 in a previous treatment cycle, OR dropped below 75 but you have additional risk factors for bleeding
- Your current platelet count is at least 100
- You have adequate organ function and are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This study tests a drug called hetrombopag to see if it can help prevent a drop in blood platelets (cells that help blood clot) caused by antibody-drug conjugate (ADC) cancer therapy. It may help patients who have already had low platelets from their treatment or are about to start an ADC regimen.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Hear when a new Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.